Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Clinical trial NCT00658775 · COMPLETED
Trial details
- NCT number
- NCT00658775
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2008-02-01
- Primary completion
- 2009-09-01
- Enrollment
- 1069
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.